Holen Sie sich die Stockscreener-App
1.06
4.95%
0.05
Handel nachbörslich:
1.10
0.04
+3.77%
Schlusskurs vom Vortag:
$1.01
Offen:
$1.02
24-Stunden-Volumen:
102.86K
Relative Volume:
1.02
Marktkapitalisierung:
$23.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-61.06M
KGV:
-0.074
EPS:
-14.3261
Netto-Cashflow:
$-59.30M
1W Leistung:
-1.85%
1M Leistung:
-3.64%
6M Leistung:
-63.45%
1J Leistung:
-74.70%
1-Tages-Spanne:
$1.02
$1.09
1-Wochen-Bereich:
$1.01
$1.10
52-Wochen-Spanne:
$1.00
$4.72
Boundless Bio Inc Stock (BOLD) Company Profile
Firmenname
Boundless Bio Inc
Sektor
Branche
Telefon
(858) 766-9912
Adresse
10955 ALEXANDRIA WAY, SAN DIEGO
Vergleichen Sie BOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.06 | 23.95M | 0 | -61.06M | -59.30M | -14.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-22 | Eingeleitet | Guggenheim | Buy |
| 2024-04-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-22 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Boundless Bio Inc Aktie (BOLD) Neueste Nachrichten
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Boundless Bio Showcases Revolutionary ecDNA Cancer Treatment at Major Goldman Sachs Healthcare Conference - Stock Titan
H.C. Wainwright initiates Boundless Bio stock with buy rating - Investing.com
HC Wainwright & Co. Initiates Coverage of Boundless Bio (BOLD) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates Boundless Bio stock with buy rating By Investing.com - Investing.com India
Boundless Bio initiated with a Buy at H.C. Wainwright - TipRanks
Boundless Bio Inc. Reports Q1 2025 Financial Results - TipRanks
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Leerink cuts Boundless Bio stock rating on program setback By Investing.com - Investing.com Nigeria
Leerink cuts Boundless Bio stock rating on program setback - Investing.com
Leerink Partners Downgrades Boundless Bio to Market Perform From Outperform, Adjusts PT to $3 From $15 - marketscreener.com
Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations - TipRanks
Boundless Bio downgraded to Market Perform from Outperform at Leerink - TipRanks
Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire
Boundless Bio changes plans for cancer drug after toxicity issues - Endpoints News
Silvercrest Asset Management Group Inc. Announces $25 Million Common Stock Repurchase Program - The Manila Times
Boundless Bio To Reduce Its Workforce By About One-third - Nasdaq
Boundless Bio Announces Portfolio Prioritization And Runway Extension - marketscreener.com
Boundless Bio Announces Major Workforce Reduction Strategy - TipRanks
Boundless Bio's Portfolio Adjustments and Streamlined Operations Boost Cash Runway - marketscreener.com
Boundless Bio discontinuing BBI-355 and BBI-825 programs - TipRanks
Boundless Bio Announces Portfolio Prioritization and Extended Operating Runway Through 2028 with Focus on Novel Combination Therapy and New Development Candidate - Nasdaq
Boundless Bio Announces Portfolio Prioritization and Runway Extension - The Manila Times
Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability - Endpoints News
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know - MSN
Boundless Bio reports R&D pipeline progress - The Pharma Letter
Boundless Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Boundless Bio Reports Q1 2025 Financial Results and Progress on BBI-355 Phase 1/2 Trial and Kinesin Program Development - Nasdaq
New Strong Sell Stocks for May 1st - The Globe and Mail
Boundless Bio’s 2024 Financial Results and Strategic Progress - MSN
Boundless Bio stock plunges to 52-week low of $1.41 - Investing.com Australia
Boundless Bio to Participate in the Needham Virtual Healthcare Conference - TradingView
Boundless Bio stock plunges to 52-week low of $1.41 By Investing.com - Investing.com UK
Boundless Bio plans $14.5M stock sale via Jefferies By Investing.com - Investing.com Australia
Boundless Bio plans $14.5M stock sale via Jefferies - Investing.com India
Boundless Bio Inc Files For Mixed Shelf Of Up To $400 MillionSEC Filing - MarketScreener
Finanzdaten der Boundless Bio Inc-Aktie (BOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):